Octreotide SC Depot in Acromegaly: Real-World Safety and Effectiveness
Official title: A Multi-Center, Multinational, Observational Study of Octreotide Subcutaneous Depot for the Treatment of Patients With Acromegaly
Run by Camurus AB · NCT07583563 · Data updated 2026-11-12
This study follows people with acromegaly who are using octreotide subcutaneous depot to see how it works and how safe it is over up to two years in everyday clinical practice.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Camurus AB Industry-sponsored |
| Locations | 7 sites (Aachen and 6 other locations) |
| Status | Recruiting |
| Started | June 5, 2026 |
| Main results expected | June 2029 |
| Study ends | June 2029 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07583563 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with acromegaly who are starting or already receiving octreotide subcutaneous depot treatment.
✕Probably not a fit
Patients who are not treated with octreotide SC depot for acromegaly or who participate in other interventional trials may not benefit from this observational study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects long-term data on the safety and effectiveness of octreotide subcutaneous depot in adults with acromegaly treated in routine care. Participants must be starting or already on octreotide SC depot for acromegaly, with follow-up through up to two years. The study emphasizes real-world outcomes rather than a controlled intervention, using non-randomized observations to document treatment experience. Data will include adverse events, biochemical markers, and clinical status as recorded in standard practice. No interventional procedures are mandated beyond standard-of-care treatment with octreotide SC depot.
Why it matters
Potential benefit: If the approach remains favorable, patients could experience sustained disease control and a better understanding of long-term safety in real-world use.
How similar studies have gone: Previous observational data have supported the safety and practicality of long-term octreotide therapy in acromegaly, though real-world evidence varies by setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have started or will be starting treatment with octreotide SC depot for acromegaly Exclusion Criteria: * Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly * Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.
Where it's running
-
Universitaetsklinikum Aachen
Aachen, Germany Recruiting -
Universitaetsklinikum Leipzig
Leipzig, Germany Recruiting -
Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie
Magdeburg, Germany Recruiting -
Universitätsklinikum Würzburg
Würzburg, Germany Recruiting -
Medicover Neuroendokrinologie MVZ
München, Germany Not yet recruiting -
Universitätsklinikum Münster
Münster, Germany Not yet recruiting
Show 1 more location
-
St James's University Hospital - Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom Not yet recruiting
Study contacts
- Study coordinator: Camurus AB
- Email: medicalinfo@camurus.com
- Phone: +46 46 286 57 30
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NTQ6179 tablets first-in-human test in healthy adults
This phase 1 study tests a single oral dose of NTQ6179 vs placebo in healthy adults to see if it is safe and how the body processes the drug.
-
Test MAR002 for acromegaly in adults on or off medical therapy
This study tests whether subcutaneous MAR002 is safe and tolerable in adults with acromegaly, compared with a placebo, over 10 weeks.
-
MAR002 in healthy men
This trial tests whether a subcutaneous injection of MAR002 is safe and tolerable in healthy men aged 18 to 40.
-
Pasireotide LAR and bone health in adults with acromegaly
This study will test whether switching adults with uncontrolled acromegaly to pasireotide LAR changes bone turnover and the risk of vertebral fractures.
-
Assessing Debio 4126 for treating acromegaly in patients on somatostatin analogs
This study is testing if a new treatment called Debio 4126 can help people with acromegaly who are already on somatostatin analogs keep their IGF-1 levels in check better than a placebo.
-
Evaluating the effects of acromegaly on hand and foot dimensions and movement
This study looks at how acromegaly affects the size and movement of hands and feet in patients to better understand the physical changes caused by the condition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.